Bupranolol: Difference between revisions
(Created page with "{{Drugbox | Verifiedfields = changed | verifiedrevid = 460123491 | IUPAC_name = (''RS'')-1-(''tert''-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol | image = Bupranolol.P...") |
No edit summary |
||
Line 55: | Line 55: | ||
| smiles = CC1=CC(=C(C=C1)Cl)OCC(CNC(C)(C)C)O | | smiles = CC1=CC(=C(C=C1)Cl)OCC(CNC(C)(C)C)O | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Bupranolol''' is a non-selective [[beta blocker]] without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to [[propranolol]]. | '''Bupranolol''' is a non-selective [[beta blocker]] without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to [[propranolol]]. | ||
==Uses and | ==Uses and Dosage== | ||
Like other beta blockers, oral bupranolol can be used to treat [[hypertension]] and [[tachycardia]]. The initial dose is 50 mg two times a day. It can be increased to 100 mg four times a day. Bupranolol eye drops (0.05%-0.5%) are used against [[glaucoma]]. | Like other beta blockers, oral bupranolol can be used to treat [[hypertension]] and [[tachycardia]]. The initial dose is 50 mg two times a day. It can be increased to 100 mg four times a day. Bupranolol eye drops (0.05%-0.5%) are used against [[glaucoma]]. | ||
Line 66: | Line 68: | ||
Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo [[first-pass metabolism]]. Bupranolol has a plasma half life of about two to four hours, with levels never reaching 1 µg/l in therapeutic doses. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid – that is, the methyl group at the benzene ring is oxidized to a [[carboxyl]] group –, of which 88% are eliminated renally within 24 hours. | Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo [[first-pass metabolism]]. Bupranolol has a plasma half life of about two to four hours, with levels never reaching 1 µg/l in therapeutic doses. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid – that is, the methyl group at the benzene ring is oxidized to a [[carboxyl]] group –, of which 88% are eliminated renally within 24 hours. | ||
== Adverse | == Adverse Effects, Contraindications, Interactions == | ||
Adverse effects, contraindications and interactions are similar to other beta blockers. | Adverse effects, contraindications and interactions are similar to other beta blockers. | ||
== References == | ==References== | ||
{{reflist|2}} | |||
{{ | {{Beta blockers}} | ||
[[Category: | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drug]] | |||
[[Category:Beta blockers]] | [[Category:Beta blockers]] | ||
Revision as of 02:49, 25 July 2014
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral, topical (eye drops) |
ATC code | |
Pharmacokinetic data | |
Bioavailability | < 10% |
Protein binding | 76% |
Metabolism | First pass elimination > 90% |
Elimination half-life | 2-4 hours (plasma) |
Excretion | > 88% renal (as carboxybupranolol) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C14H22ClNO2 |
Molar mass | 271.78298 g/mol |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
WikiDoc Resources for Bupranolol |
Articles |
---|
Most recent articles on Bupranolol |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Bupranolol at Clinical Trials.gov Clinical Trials on Bupranolol at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Bupranolol
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Bupranolol Discussion groups on Bupranolol Patient Handouts on Bupranolol Directions to Hospitals Treating Bupranolol Risk calculators and risk factors for Bupranolol
|
Healthcare Provider Resources |
Causes & Risk Factors for Bupranolol |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to propranolol.
Uses and Dosage
Like other beta blockers, oral bupranolol can be used to treat hypertension and tachycardia. The initial dose is 50 mg two times a day. It can be increased to 100 mg four times a day. Bupranolol eye drops (0.05%-0.5%) are used against glaucoma.
Pharmacology
Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo first-pass metabolism. Bupranolol has a plasma half life of about two to four hours, with levels never reaching 1 µg/l in therapeutic doses. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid – that is, the methyl group at the benzene ring is oxidized to a carboxyl group –, of which 88% are eliminated renally within 24 hours.
Adverse Effects, Contraindications, Interactions
Adverse effects, contraindications and interactions are similar to other beta blockers.
References
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- Articles with changed CASNo identifier
- Articles with changed KEGG identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Cardiovascular Drugs
- Drug
- Beta blockers